Combination thrombolytic therapy: A comparison of simultaneous and sequential regimens of tissue plasminogen activator and urokinase

Coronary angioplasty following unsuccessful tissue plasminogen activator (t-PA) therapy for acute myocardial infarction has been associated with a high incidence of subsequent reocclusion of the infarct-related artery, and a relatively high in-hospital mortality. In contrast, the combination of t-PA and urokinase, when given intravenously prior to coronary angiography, appears to be associated with a low incidence of post-rescue angioplasty reocclusion. In order to determine whether intraprocedural urokinase, given at the time of rescue coronary angioplasty for failed t-PA therapy, improves long-term patency of the infarct vessel to the same extent as preangiographic, combination t-PA/urokinase therapy, three thrombolytic treatment strategies were retrospectively compared. The first group included 86 patients undergoing rescue angioplasty after t-PA monotherapy (t-PA alone). The clinical and angiographic outcomes of these patients were compared with those of 24 patients who received intravenous or intracoronary urokinase during rescue angioplasty following unsuccessful t-PA therapy (sequential t-PA/urokinase therapy), and with those of 34 patients undergoing rescue coronary angioplasty following unsuccessful therapy with the combination of intravenous t-PA and urokinase (simultaneous therapy). There was no difference in postangioplasty patency rate of the infarct-related artery between the three groups. However, the sequential t-PA/urokinase regimen was associated with a subsequent reocclusion rate that was lower than the rate that occurred in the t-PA monotherapy group but higher than the rate in the simultaneous t-PA/urokinase group (13 versus 29 versus 2%, respectively; \( p = 0.003 \)). In-hospital mortality in the sequential therapy group was 12% compared with 12% in the t-PA monotherapy group and 0% in the simultaneous t-PA/urokinase group \( (p = 0.10) \). There was no significant difference between the groups in the incidence of bleeding or in the need for emergency coronary artery bypass graft surgery. We conclude that the addition of intracoronary or intravenous urokinase at the time of rescue coronary angioplasty may improve the long-term patency of the infarct-related artery following intravenous t-PA therapy, but that the initial, preangiographic administration of combined t-PA and urokinase appears to be a preferable treatment regimen for patients in whom rescue coronary angioplasty appears likely. (Am Heart J 1991;122:375.)

Jonathan A. Morris, David W. M. Muller, MBBS, and Eric J. Topol, MD.
Ann Arbor, Mich.

Previous studies\(^1,2\) have demonstrated that the early intravenous administration of tissue plasminogen activator (t-PA) following acute myocardial infarction results in a 90-minute infract-related arterial patency rate of approximately 75%, but that subsequent reocclusion rates are relatively high. Reocclusion rates may be particularly high after emergency coronary angioplasty for failed t-PA therapy.\(^3\) Urokinase and other nonfibrin-specific thrombolytic agents tend to have both lower early patency rates and lower reocclusion rates,\(^4\) the latter due perhaps to a greater reduction in circulating fibrinogen and greater gen-
eration of fibrin (ogen) degradation products. Several studies have evaluated the use of combination thrombolytic therapy. Early canine models suggested that the combination of intravenous urokinase (or its precursor, pro-urokinase) with t-PA may have synergistic fibrinolytic effects, and early pilot studies suggested a favorable clinical outcome in patients treated with combinations of t-PA and pro-urokinase or t-PA and urokinase. The improved clinical outcome noted in the latter study was recently confirmed in a larger, randomized clinical trial that showed that the concomitant administration of intravenous urokinase and t-PA resulted in early and sustained myocardial reperfusion with fewer adverse clinical effects when compared with intravenous t-PA alone.

These findings raise the question of the value of sequential (as opposed to simultaneous) combination thrombolytic therapy in the subgroup of patients whose infarct-related artery remains occluded following thrombolytic monotherapy. The specific purpose of this retrospective study was to determine whether the administration of intracoronary or intravenous urokinase improves short- and long-term infarct vessel patency rates and the clinical outcome of patients requiring rescue coronary angioplasty following failed intravenous t-PA therapy. The clinical and angiographic outcomes of patients undergoing rescue angioplasty following three different thrombolytic treatment regimens were therefore compared. These included: (1) a group receiving intravenous t-PA therapy alone, (2) a group receiving initial intravenous t-PA and subsequent intracoronary or intravenous urokinase (given at the time of rescue coronary angioplasty), and (3) a group that received both intravenous t-PA and urokinase prior to coronary angiography and rescue angioplasty.

**METHODS**

**Patient selection.** The records of all adult cardiac catheterizations performed between March 1987 and December 1989 at the University of Michigan Medical Center were reviewed to identify patients with acute myocardial infarction who had presented with electrocardiographic changes of at least 0.1 mV ST segment elevation in two or more contiguous leads, and who had been treated with intravenous t-PA within 6 hours of symptom onset. Patients were selected for inclusion in the sequential t-PA/urokinase group if (1) cardiac catheterization performed within 6 hours of symptom onset had shown persistent occlusion of the infarct-related artery, (2) rescue coronary angioplasty was attempted, and (3) intracoronary and/or intravenous urokinase was given during the acute interventional procedure. This group, the sequential thrombolysis group, was then compared with the group of patients enrolled in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) study who required rescue coronary angioplasty for failed t-PA therapy (t-PA alone) and a similar group undergoing rescue coronary angioplasty following failed combination t-PA and urokinase (simultaneous t-PA/urokinase) therapy in the TAMI-2 and TAMI-5 studies. The patients receiving the latter two drug regimens fulfilled the same entry criteria as the first group and underwent cardiac catheterization within 90 minutes of the initiation of the thrombolytic infusion.

**Fibrinolytic therapy.** In two of the groups, t-PA (Acti- vase, Genentech, South San Francisco, Calif.) was administered as an infusion of 60 mg in the first hour, with 6 mg as a bolus dose, followed by 20 mg/hr for the next 2 hours to a total dose of 100 mg. Patients enrolled in the TAMI 2 and TAMI 5 studies (simultaneous therapy) received 1 mg/kg t-PA (to a maximum of 90 mg) over 60 minutes with 10% given as a bolus dose. In the sequential thrombolysis group, intracoronary urokinase (Abbokinase, Abbott Laboratories, Chicago Ill.) was administered in doses ranging from 250,000 to 1,500,000 units before, during, or after balloon angioplasty with or without additional infusions of intravenous urokinase. The dosage and timing of drug delivery were at the discretion of the angiographer. Patients in the simultaneous t-PA/urokinase group received, in addition to intravenous t-PA, urokinase as an infusion of 0.5, 1.0, or 1.5 million units over 60 minutes.

**Cardiac catheterization.** Following initiation of the thrombolytic regimen, femoral arterial and venous access was obtained as soon as possible, heparin (5000 U) was administered intravenously, and coronary angiography of both the infarct-related and the non-infarct-related arteries was performed in multiple projections. Following demonstration of persistent occlusion of the infarct-related artery and suitable coronary anatomy, rescue coronary angioplasty was attempted. The initial success of the procedure was determined on the basis of the patency status of the infarct vessel at the completion of the procedure. Repeat cardiac catheterization was performed 7 to 10 days after the patient's admission into the study to determine the infarct vessel patency status and the extent of recovery of the infarct zone wall motion. Intercurrent coronary angiography was also performed for recurrent myocardial ischemia or hemodynamic instability.

**Evaluation of subsequent outcome.** The clinical and angiographic variables evaluated included infarct vessel patency and reocclusion rates, major hemorrhagic episodes, the need for emergency coronary angioplasty or bypass graft surgery, and death prior to hospital discharge. All clinical data were obtained by a review of cineangiograms and from cardiac catheterization reports, nursing records, transfusion records, progress notes, and the hospital discharge summary.

**Definition of clinical variables.** The infarct-related artery was considered to be patent if there was antegrade Thrombolysis In Myocardial Infarction (TIMI) grade 2 or 3 flow, and nonpatent if coronary flow was TIMI grade 0 or 1. Reocclusion was defined as TIMI grade 0 or 1 flow in a previously patent infarct-related artery at repeat coronary angiography any time prior to hospital discharge. Coronary angiography was considered to be patent if there was antegrade TIMI grade 2 or 3 flow, and nonpatent if coronary flow was TIMI grade 0 or 1. Reocclusion was defined as TIMI grade 0 or 1 flow in a previously patent infarct-related artery at repeat coronary angiography any time prior to hospital discharge. Coronary angiography was considered to be patent if there was antegrade TIMI grade 2 or 3 flow, and nonpatent if coronary flow was TIMI grade 0 or 1. Reocclusion was defined as TIMI grade 0 or 1 flow in a previously patent infarct-related artery at repeat coronary angiography any time prior to hospital discharge.
angioplasty was considered to be successful if it resulted in patency of the infarct-related artery with a residual stenosis less than 50% of the luminal diameter. Coronary angioplasty and bypass graft surgery were considered to be emergency procedures if they were performed urgently for symptoms of recurrent myocardial ischemia or if the patient was transferred directly from the cardiac catheterization laboratory to the operating room. Major hemorrhage was defined as potentially life-threatening intracranial or intraabdominal bleeding, and in-hospital mortality included death from any cause occurring prior to discharge from the hospital regardless of the duration of hospitalization.

Statistics. Differences in clinical and angiographic outcomes between the three groups were compared using chi square analysis. A two-tailed probability of less than 0.05 was considered to be statistically significant.

RESULTS

Baseline characteristics. Baseline demographic and angiographic characteristics were similar in the three groups (Table I). In the sequential t-PA/urokinase group, urokinase administration was initiated 3.3 ± 1.8 hours after intravenous t-PA administration was commenced, and was given as an intracoronary dose of 0.9 ± 0.4 million units and as an intravenous infusion of 0.9 ± 0.5 million units. The mean age in this group was 57 years, 88% of the patients were men, and the infarct-related artery was the left anterior descending artery in 40%, the right coronary artery in 54%, the left circumflex in 4%, and the left main coronary artery in 4%. Group 2 consisted of 86 patients who underwent rescue coronary angioplasty following t-PA alone in the TAMI- Study, and group 3 consisted of 22 patients in the TAMI- Study and 12 patients in the TAMI-5 Study who underwent rescue angioplasty following simultaneous t-PA/urokinase therapy. No difference was apparent in the mean age, sex distribution, prevalence of coronary risk factors, or site of infarction between these three groups.

Patency of the infarct-related artery. Initial angiography showed complete occlusion (TIMI grade 0 or 1 flow) of the infarct-related artery in all patients in each of the three groups. Following attempted rescue coronary angioplasty, the patency rates were similar for each of the thrombolytic regimens (Table II). Sequential t-PA and urokinase therapy was associated with a 96% patency rate, compared with a patency rate of 89% in the t-PA monotherapy group and of 94% in the simultaneous t-PA/urokinase group (p = NS). The incidence of reocclusion was, however, significantly different between the three groups (Table II). The reocclusion rate in the sequential t-PA/urokinase group was 14%, lower than the rate that occurred in the t-PA monotherapy group (29%), but significantly higher than the 2% reocclusion rate that followed the simultaneous t-PA and urokinase regimen (p = 0.003).

Clinical outcome. The incidence of major, potentially life-threatening hemorrhage, the need for emergency coronary angioplasty or bypass graft surgery, and the in-hospital mortality are summarized in Table II. There was no apparent difference between the groups in the incidence of bleeding or of recurrent myocardial ischemia requiring emergency revascularization. The in-hospital mortality rate, on the other hand, was similar in the groups receiving t-PA alone and sequential t-PA/urokinase therapy (12% and 13%, respectively), but the in-hospital mortality following rescue angioplasty after unsuccessful si-
multaneous t-PA/urokinase therapy was 0%. This apparently lower mortality in the latter group did not reach statistical significance (p = 0.10).

**DISCUSSION**

Following the recent demonstration that the combination of intravenous t-PA and urokinase is associated with a higher long-term infarct vessel patency rate than the administration of either drug alone, this retrospective study sought to determine whether the sequential administration of intravenous t-PA and intracoronary urokinase has similar efficacy to simultaneous t-PA/urokinase group, the reocclusion modalities are similar when compared with the ever, which suggests that the rapid determination of creatine kinase isoenzymes and myoglobin release, or the continuous monitoring of ST segment shifts, may allow accurate identification of patients who fail to achieve early thrombolysis and reperfusion. Should these prove to have a consistently high sensitivity and specificity, then the frequency with which rescue coronary angioplasty is attempted may well increase significantly. On the basis of the findings of this study, it seems appropriate to consider the early administration of intravenous urokinase following t-PA to those patients in whom the need for coronary angiography and rescue coronary angioplasty appears likely. This approach appears to be safe and to be associated with a better clinical outcome than if urokinase is withheld until the time of the interventional procedure. If, on the other hand, coronary angiography demonstrates persistent occlusion of the infarct-related artery in a patient who has received t-PA alone, the addition of intravenous and/or intracoronary urokinase may improve the prospects for long-term infarct vessel patency.

**Implications for patient management.** Although some aggressive interventional centers adhere to a policy of routinely performing emergency coronary angiography in all patients presenting with acute myocardial infarction, most centers currently employ a more conservative approach. In the absence of reliable noninvasive markers of reperfusion, this latter approach excludes the possibility of rescue angioplasty. Recent preliminary data have been reported, however, which suggest that the rapid determination of creatine kinase isoenzymes and myoglobin release, or the continuous monitoring of ST segment shifts, may allow accurate identification of patients who fail to achieve early thrombolysis and reperfusion. Should these prove to have a consistently high sensitivity and specificity, then the frequency with which rescue coronary angioplasty is attempted may well increase significantly. On the basis of the findings of this study, it seems appropriate to consider the early administration of intravenous urokinase following t-PA to those patients in whom the need for coronary angiography and rescue coronary angioplasty appears likely. This approach appears to be safe and to be associated with a better clinical outcome than if urokinase is withheld until the time of the interventional procedure. If, on the other hand, coronary angiography demonstrates persistent occlusion of the infarct-related artery in a patient who has received t-PA alone, the addition of intravenous and/or intracoronary urokinase may improve the prospects for long-term infarct vessel patency.

**Alternative pharmacologic approaches.** One small, nonrandomized study has suggested that the combination of intravenous t-PA and streptokinase may also be associated with an increased long-term patency rate following rescue angioplasty. This regimen has the advantage of a significant savings in the cost of the thrombolytic agents but has an increased potential for hemodynamic and allergic side effects. The efficacy of intracoronary streptokinase following
failed t-PA therapy has not been reported. Although not specifically tested in the setting of rescue coronary angioplasty, several other pharmacologic agents have been shown in experimental studies to reduce the reocclusion rate following t-PA therapy. These agents include monoclonal antibodies to platelet glycoprotein IIb/IIIa receptor, thromboxane A2 antagonists, and specific inhibitors of thrombin including hirudin, a naturally occurring component of leech saliva.

Limitations. The principal limitations of this study are its retrospective nature and the relatively small size of the groups studied. Although the baseline demographic and angiographic characteristics appear to be similar in each group, in the absence of a large, randomized trial, important differences may have occurred. A further limitation is the lack of control of the timing, dosage, or route of administration of urokinase in the sequential therapy group, a limitation inherent in any retrospective, observational study.

Conclusions. The findings of this study suggest that the periprocedural use of urokinase may improve the clinical and angiographic outcome of patients in whom rescue angioplasty is performed for failed t-PA thrombolysis. Although this regimen appears to be whom rescue angioplasty is performed for failed t-PA therapy has not been reported. Although this regimen appears to be whom rescue angioplasty is performed for failed t-PA therapy has not been reported.

REFERENCES


18. Ellis AK, Little T, Masud ARZ, Liberman HA, Morris DC, Klocke FJ. Early noninvasive detection of successful reperfus-
Early angioplasty in patients with acute myocardial infarction complicated by hypotension

Emergency percutaneous transluminal coronary angioplasty was performed in 62 patients with acute myocardial infarction complicated by hypotension. All patients were treated within 12 hours of the onset of chest pain. Angioplasty was completely successful (residual lesion ≤50%) in 48 patients, partially successful (patent vessel >50% residual lesion) in four patients, and unsuccessful in 10 patients. Patients in whom angioplasty was successful had a hospital mortality rate of 19%; those in whom angioplasty was unsuccessful or only partially successful had hospital mortality rates of 60% and 50%, respectively (p = 0.012). Patients with occlusion of the proximal left anterior descending vessel had the highest failure rate (42%) and the highest mortality rate (67%). Other univariate predictors of hospital mortality were older age and elevated end-diastolic pressure. Successful emergency angioplasty improves mortality in patients with acute infarction complicated by hypotension. (AM HEART J 1991;122:380.)